Targeting specific proteins in cancer cells to improve treatment for head and neck cancers
Targeting miRNA-loaded exosomes to HNSCC with Dsg2-directed scFv fusion proteins
This study is looking at a new way to treat head and neck cancer by using special immune cells to target a protein that some aggressive tumors have too much of, with the goal of finding better and more personalized treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10811446 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for head and neck squamous cell carcinomas (HNSCC) by targeting a specific protein called desmoglein 2 (Dsg2) that is often overexpressed in aggressive tumors. The approach involves using engineered immune cells (CAR-T cells) that can recognize and attack cancer cells expressing Dsg2. By understanding the mechanisms that allow some tumors to resist current therapies, the research aims to develop more effective and personalized treatment options for patients. The study will also explore the role of small extracellular vesicles in cancer progression and treatment response.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma who may not be responding to current immunotherapy treatments.
Not a fit: Patients with early-stage head and neck cancers or those who do not express the Dsg2 protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized therapies for patients with head and neck cancers, potentially improving their treatment outcomes.
How similar studies have performed: Other research has shown promising results using similar targeted approaches in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Mahoney, My Georgia — Thomas Jefferson University
- Study coordinator: Mahoney, My Georgia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.